Skip to main content
Advanced tissue processing laboratory with precision medical equipment
Infrastructure for Regenerative Medicine

Precision Tissue Processing.
Reproducible Results.

Graftworks provides the automated harvesting and processing platform that transforms umbilical cord tissue into uniform, clinically usable grafts — replacing manual, inconsistent methods with patented precision.

Two Markets. One Platform.

Our automated tissue processing platform serves the complete spectrum of cord tissue applications — from private banking to clinical wound care.

Autograft & Cryopreservation

Enabling private cord blood banks to unlock new revenue from stored tissue. Our platform processes umbilical cord into bankable autograft products with maximized cell recovery.

Learn More

Allograft & Tissue Harvesting

Providing tissue manufacturers a reproducible, automated method for harvesting Wharton's Jelly allografts — enabling vertical integration and consistent graft quality at scale.

Learn More
The Industry Problem

95% of Cord Tissue Goes to Waste

Umbilical cord tissue — specifically Wharton's Jelly — is one of medicine's most valuable biological assets, rich in mesenchymal stem cells, hyaluronic acid, and growth factors. Yet the vast majority is discarded.

Current harvesting methods are manual, taking 2+ hours per cord with "artisan" techniques that produce variable graft quality and high rejection rates. The industry cannot scale to meet surging demand for wound care and regenerative therapies.

2+ hrs
Manual Processing Time
Researchers processing tissue samples in advanced laboratory setting
University of Texas-Houston research laboratory
Exclusive Partnership

McGovern Medical School at University of Texas-Houston

Graftworks holds exclusive rights from McGovern Medical School at University of Texas-Houston for patented tissue processing automation — the foundation of our entire platform.

This partnership bridges academic innovation in regenerative medicine with commercial-scale manufacturing, backed by three issued U.S. patents covering devices and methods for cord tissue harvesting.

  • Exclusive rights to patented harvesting automation.
  • Three issued U.S. patents (devices and methods).
  • FDA Section 361 HCT/P pathway — no clinical trials required.
Learn About the Partnership

Ready to Transform Your Tissue Processing?

Whether you're a cord blood bank, tissue manufacturer, or healthcare supplier — Graftworks has a solution for you.

Contact Us